Publicaciones en las que colabora con María Socorro Espuelas Millán (25)

2022

  1. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

2016

  1. Novel heteroaryl selenocyanates and diselenides as potent antileishmanial agents

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 6, pp. 3802-3812

2015

  1. Leishmanicidal activities of novel methylseleno-imidocarbamates

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 9, pp. 5705-5713

2014

  1. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis

    Expert Opinion on Drug Delivery, Vol. 11, Núm. 4, pp. 579-597

  2. Novel hybrid selenosulfonamides as potent antileishmanial agents

    European Journal of Medicinal Chemistry, Vol. 74, pp. 116-123

  3. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) - Pluronic® F127 copolymers for controlled protein release

    International Journal of Pharmaceutics, Vol. 459, Núm. 1-2, pp. 1-9

  4. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation

    European Journal of Pharmaceutical Sciences, Vol. 62, pp. 309-316

2012

  1. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies

    Current Medicinal Chemistry, Vol. 19, Núm. 25, pp. 4259-4288

  2. Nanoparticles and microparticles for allergen immunotherapy

    Journal of investigational allergology & clinical immunology, Vol. 22, Núm. suppl. 1, pp. 7-15

2011

  1. Nanomedicine: Novel approaches in human and veterinary therapeutics

    Veterinary Parasitology, Vol. 180, Núm. 1-2, pp. 47-71

2010

  1. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination

    Frontiers in Bioscience - Scholar, Vol. 2 S, Núm. 3, pp. 876-890

2009

  1. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne

    Journal of Immunological Methods, Vol. 348, Núm. 1-2, pp. 1-8

  2. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis

    International Archives of Allergy and Immunology, Vol. 149, Núm. 2, pp. 111-118

2008

  1. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 70, Núm. 3, pp. 711-717

  2. Applications of particulate drug delivery systems in the control of an intracellular bacterial pathogen

    Handbook of particulate drug delivery (American Scientific Publishers), pp. 325-346

  3. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 70, Núm. 1, pp. 98-108

  4. Mannose-targeted systems for the delivery of therapeutics

    Expert Opinion on Drug Delivery, Vol. 5, Núm. 6, pp. 703-724

2007

  1. Gamma interferon loaded onto albumin nanoparticles: In vitro and in vivo activities against Brucella abortus

    Antimicrobial Agents and Chemotherapy, Vol. 51, Núm. 4, pp. 1310-1314

  2. Intradermal immunization with ovalbumin-loaded poly-ε-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice

    Clinical and Experimental Allergy, Vol. 37, Núm. 2, pp. 287-295